Trials / Terminated
TerminatedNCT00492388
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Detailed description
The primary objective is to evaluate the safety and efficacy following the administration of intranasal ketamine in providing pain relief as compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PMI-150 (intranasal ketamine) | intranasal dosing |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2007-06-27
- Last updated
- 2012-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00492388. Inclusion in this directory is not an endorsement.